Physician profile
Nitin R Patel
NPI 1770511156
$2,897.25
in general payments reported to CMS, 2019-2025
24 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $97.57 · 2021: $502 · 2022: $459 · 2023: $715 · 2024: $458 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $376.44 | 2022-2025 | Auvelity |
| Abbvie INC. | $339.05 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $320.21 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $248.27 | 2019-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $218.95 | 2019-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $184.75 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $155.76 | 2022-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $154.08 | 2021-2025 | Austedo, Austedo Xr |
| Allergan, INC. | $129.44 | 2019 | |
| Bausch Health US, LLC | $119.67 | 2020-2025 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.27 | 2021-2025 | Caplyta |
| Almatica Pharma LLC | $83.29 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $80.36 | 2020-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $79.24 | 2024 | Cobenfy |
| Alkermes, INC. | $55.39 | 2023-2025 | Lybalvi, Vivitrol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $51.57 | 2023 | Ingrezza |
| Shire North American Group INC | $48.82 | 2019 | |
| Corium, LLC | $30.59 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $30.18 | 2025 | Jornay Pm |
| Nevro Corp. | $28.88 | 2024 | Senza |
| Alfasigma USA, INC. | $22.93 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.58 | 2022 | |
| Noven Therapeutics, LLC | $16.98 | 2024 | Secuado, Xelstrym |
| Kls-Martin L.P. | $9.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.